A case study of lean drug discovery: from project driven research to innovation studios and process factories

Ullman, Fredrik; Boutellier, Roman

doi:10.1016/j.drudis.2008.03.011

Cited by 38 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research findings provided insights supported by the extant literature and that can be used to address entrepreneurial collaborative solutions in interactions with clients to adapt to changing research environment (Lustig & Thompson, 2013;Ullman & Boutellier, 2008). Findings further indicated that the role of management is very critical in an organization that is undergoing change in effective communication culture and adequate sharing of information with the client base; by encouraging the breadth of services they are supporting clients with, and that influences organizational strategy and our operating plan (Kaitin, 2010;Sams-Dodd, 2013).…”

Section: Trust and Commitment In Inter-firm Relationshipsmentioning

confidence: 91%

“…A corporate entrepreneurship framework offers a means for better understanding, within the context of strategic change (Stevenson, 1983), managers' perceptions of technical and organizational maturity, efficient governance, and maintaining high-performance teams in an organization (Baum et al, 2011;Lustig & Thompson, 2013;Ullman & Boutellier, 2008). Given that strategic change is an inevitable factor in the life cycle of modern organizations, the findings from this study contribute to a better understanding of how change in organizations can be successfully and more effectively implemented, as well as how to forecast allocation of resources so as to bring about the desired change (Kaitin, 2010;Mirowski & Van Horn, 2005).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Corporate Entrepreneurship in Pharma R&D Organizational Transformations

Dibirov¹

2016

JMAA

View full text Add to dashboard Cite

This multiple-case study examined factors that could contribute to a richer understanding of top managers' perceptions on maintaining high-performance teams in Pharma R&D. In addition, this multiple-case study investigated top managers' perceptions of building opportunity-based entrepreneurial culture in organizations during strategic change, considered as a critical factor for organizations during change, the results of which can be used to guide management in preventing destructive actions of business non-loyalty. Following, this multiple-case study examined the management of change within the corporate entrepreneurship literature as a means of helping organizations improve practical intelligence of defining growth goals and new enterprise growth management processes and procedures, including those relevant to change, the way they function, and formal and informal rules protecting adequacy of governance arrangements as well as the organizational culture. Participant responses to the interview question regarding capability to maintain high-performing teams resulted in themes regarding role of leadership in risk management approach, leadership development challenges, trust and commitment in inter-firm relationships, as being the top managers' perceptions and the attitudes in outsourcing R&D industry sector since the enactment of the strategic change.

show abstract

Section: Trust and Commitment In Inter-firm Relationshipsmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Corporate Entrepreneurship in Pharma R&D Organizational Transformations

Dibirov¹

2016

JMAA

View full text Add to dashboard Cite

show abstract

“…[5][6][7]). Others focus more on the effectiveness paradigm and want to find the right target and process as early as possible through timely communication and collaboration in project teams [8].…”

Section: Introductionmentioning

confidence: 97%

A new application of value-stream mapping in new drug development: a case study within Novartis

Heinzen

Mettler

Coradi

et al. 2015

Drug Discovery Today

View full text Add to dashboard Cite

“…Initiatives like six sigma and lean thinking focus on the improvement of the efficiency of the complete discovery process while maintaining the quality [5,6]. As a result, high-throughput synthesis (combinatorial chemistry), efficient purification procedures or (open access) purity analysis, fast screening of various physicochemical properties and metabolic stability, high-throughput screening technologies for target-ligand screening (IC50 assays) and functional assays have all received tremendous attention [7].…”

mentioning

confidence: 99%

MS Applications in Support of Medicinal Chemistry Sciences

Honing¹,

Ingelse²,

Pramanik³

2013

Mass Spectrometry for Drug Discovery and Drug Development

View full text Add to dashboard Cite

In the drug discovery process, medicinal chemistry plays a crucial role in the optimal design and synthesis (production) of new chemical entities (NCEs) or new biological entities (NBEs); this is true for a single entity as well as a complete compound library. A key requirement in this field of science is the optimization of both the chemical and the biological properties of these potential drug-like compounds. Important criteria are the design of efficient synthesis routes, the balancing of the physical chemical properties with optimal in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) processes, and a profound understanding of the pharmacodynamics in the appropriate pharmacological models. In the lead optimization stage, an important step is scaling up the synthesis route as needed for the execution of toxicology studies and the screening of suitable drug formulations. In summary, medicinal chemistry support includes participating in a large variety of activities and decision making processes that play a key role in the search for either a "first in class" new drug or a "best in class" new drug [1].These "drug discovery" processes are continuously under pressure, as the research and development (R&D) costs continue to increase and more data are requested before new drug candidates are taken into (pre-)clinical development. Hence, the choice of "targeted" high-throughput screening (HTS) libraries, the process of hit appraisal, and the understanding of target-ligand interactions can be considered the starting points for a new drug discovery program [2]. Next, the main focus is on the discovery of a lead compound; typically, this is a compound showing promising data regarding target affinity, reasonable efficacy in cellular models, good physical chemical parameters (i.e., a "drug-like" compound), and acceptable oral bioavailability in Mass Spectrometry for Drug Discovery and Drug Development, First Edition. Edited by Walter A. Korfmacher.

show abstract

A case study of lean drug discovery: from project driven research to innovation studios and process factories

Cited by 38 publications

References 11 publications

Corporate Entrepreneurship in Pharma R&D Organizational Transformations

Corporate Entrepreneurship in Pharma R&D Organizational Transformations

A new application of value-stream mapping in new drug development: a case study within Novartis

MS Applications in Support of Medicinal Chemistry Sciences

Contact Info

Product

Resources

About